Mary Reilly joined the Opsona management team in March 2005 to head up the pharmaceutical development of its pre-clinical candidates.
Her role is to direct the development of lead compounds from discovery through pharmaceutical development including chemistry, manufacturing and controls (CMC) and their progression through the clinic.
She has extensive experience in drug development from late-stage discovery to registration and approval of products at all stages of the development cycle within Europe and the USA.
Before joining Opsona she worked for 15 years with Elan Pharmaceuticals where she was Associate Director and Project Leader for development projects. She also has experience in parenteral sterile drug development, manufacture and registration.
Mary Reilly currently oversees the Pharmaceutical and Clinical Development on OPN-305 and is also responsible for Operations. She has QP qualifications in line with EU clinical directive 2001/20/EC.